The UK biotech, launched with $410 million, ended the switch study after enrolling just eight of 120 planned patients, citing market evolution.
Recap by typeshit. Full story at Fierce Biotech.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
NewsNation covers research aimed at the weight many people put back on once they come off GLP-1 medications.
A short social post from CPOHealth on how GLP-1 drugs lower appetite and blood sugar, with a reminder that side effects come with them.
Loading…